Supercharged immune cells take on childhood cancers

NCT ID NCT03721068

Recruiting now Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new treatment for children whose neuroblastoma or osteosarcoma has come back or not responded to standard therapy. The treatment uses the patient's own T-cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to check safety and find the best dose, with 18 participants expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Gaucher disease neuroblastoma osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA OSTEOSARCOMA

Contacts and locations

Locations

Emory - Winship Cancer Institute
WITHDRAWN

Atlanta, Georgia, 30322, United States
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27599-7295, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.